EIDD-1931 (EIDD1931; Beta-d-N4-hydroxycytidine; NHC) is a novel and potent ribonucleoside analog with antiviral activity. EIDD-1931 is an active metabolite of the UK-approved anti-COVID-19 drug Molnupiravir (EIDD2801; prodrug-EIDD1931; MK-4482; Lagevrio), thus has the potential to be used as an anti-COVID-19 drug. EIDD-1931 has a broad spectrum antiviral activity and can inhibit replication of severe acute respiratory syndrome coronavirus (SARS-CoV) in Vero 76 cells, Middle East respiratory syndrome coronavirus (MERS-CoV) in Calu-3 2B4 cells, and SARS-CoV-2 in Vero cells (IC 50 s =0.1, 0.15 and 0.3 μM, respectively. It has increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir.

纯度：≥98%

CAS： 3258-02-4